Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameLepu Bio
Stock Code02157
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities一家聚焦於腫瘤治療領域的生物製藥企業,已構建多個腫瘤產品管線,包括八種臨床階段候選藥物、三種臨床前候選藥物及三種臨床階段的候選藥物的聯合療法。候選藥物涵蓋靶向療法(包括ADC)及免疫治療(包括PD-1/PD-L1抗體及溶瘤病毒)等。
Listing Date2022-02-23
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)上海市閔行區蘇召路1628號1幢C280室
Business Address (Hong Kong)香港灣仔皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitelepubiopharma.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism 18A生物科技
Offer PriceHK$ 7.13 / shares
Offer Price RangeFinal offer price only, no range
Lot Size1,000 shares
Entry ThresholdHK$ 7,130
Par ValueRMB 1.0 / shares
Offer Period2022-02-10 to 2022-02-15
Global Offering Shares126,876,000 shares
HK Public Offer Shares (Initial)12,688,000 shares (10.0%)
Public Offer Lots (Initial)12,688lots (Pool A6,344lots,Pool B6,344lots)
International Placing Shares (Initial)114,188,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,658,545,838 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share43.1%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 904,625,880

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 1,000 HK$ 7,130
2 lots 2,000 HK$ 14,260
3 lots 3,000 HK$ 21,390
4 lots 4,000 HK$ 28,520
5 lots 5,000 HK$ 35,650
6 lots 6,000 HK$ 42,780
7 lots 7,000 HK$ 49,910
8 lots 8,000 HK$ 57,040
9 lots 9,000 HK$ 64,170
10 lots 10,000 HK$ 71,300
15 lots 15,000 HK$ 106,950
20 lots 20,000 HK$ 142,600
25 lots 25,000 HK$ 178,250
30 lots 30,000 HK$ 213,900
35 lots 35,000 HK$ 249,550
40 lots 40,000 HK$ 285,200
45 lots 45,000 HK$ 320,850
50 lots 50,000 HK$ 356,500
60 lots 60,000 HK$ 427,800
70 lots 70,000 HK$ 499,100
80 lots 80,000 HK$ 570,400
90 lots 90,000 HK$ 641,700
100 lots 100,000 HK$ 713,000
200 lots 200,000 HK$ 1,426,000
300 lots 300,000 HK$ 2,139,000
400 lots 400,000 HK$ 2,852,000
500 lots 500,000 HK$ 3,565,000
600 lots 600,000 HK$ 4,278,000
700 lots 700,000 HK$ 4,991,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
900 lots 900,000 HK$ 6,417,000
1,000 lots 1,000,000 HK$ 7,130,000
3,000 lots 3,000,000 HK$ 21,390,000
4,000 lots 4,000,000 HK$ 28,520,000
5,000 lots 5,000,000 HK$ 35,650,000
6,344 lots 6,344,000 HK$ 45,232,720

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 7.59B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 11,825,431,824
H-Share Market Cap (at Offer Price)HK$ 11,438,498,389
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status經營虧損人民幣520.4百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Balance Sheet
Item 201920202021-08
Cash and cash equivalents 188,545402,867261,194
Inventories 8,08219,56924,164
Total current assets 221,539843,349550,795
Total assets 1,525,2812,423,6112,207,026
Total current liabilities 1,215,636382,221278,675
Total liabilities 1,710,921921,8891,027,024
Total equity -185,6401,501,7221,180,002
Equity attributable to owners -352,5001,473,5111,163,609
Cash Flow Statement
Item 201920202021-08
Net cash from operating activities -233,994-422,689-418,322
Net cash from investing activities -415,318-749,669-13,519
Net cash from financing activities 770,3941,386,679291,140
Net increase in cash 121,082214,321-140,701
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 7.14
First Day OpenHK$ 7.13
First Day Change0.14%
First Day Volume15827000.0
First Day Turnover112031000.0
Use of Proceeds
1、將分配約551.0百萬港元(占所得款項凈額的68.5%)為核心產品撥資; 2、將分配約51.0百萬港元(占所得款項凈額的6.3%)為公司的其他主要臨床階段候選藥物及公司的主要臨床前候選藥物撥資; 3、將分配約127.0百萬港元(占所得款項凈額的15.8%)用于收購有潛力的技術及資產及擴張公司的候選藥物管線; 4、將分配約75.2百萬港元(占所得款項凈額的9.4%)用作一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 Morgan Stanley Asia Limited CE AAD291
Overall Coordinators (2)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 Morgan Stanley Asia Limited CE AAD291
Joint Bookrunners (6)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 Morgan Stanley Asia Limited CE AAD291 海通国际证券有限公司 CE AAF806 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 中国银河国际证券(香港)有限公司 CE AXM459 VALUABLE CAPITAL LIMITED CE AUL711
Joint Lead Managers (7)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 Morgan Stanley Asia Limited CE AAD291 海通国际证券有限公司 CE AAF806 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 中国银河国际证券(香港)有限公司 CE AXM459 VALUABLE CAPITAL LIMITED CE AUL711 老虎证券(香港)环球有限公司 CE BMU940

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 King Star Med LP 155,854,670 HKD — 17.23% — 6 months 2022-08-23
2 Vivo Funds 233,785,570 HKD — 25.84% — 6 months 2022-08-23

Directors & Management

PositionChinese nameEnglish Name
Chairman蒲忠傑—
Company Secretary李昀軼、黎少娟—
No director data available.

Major Shareholders

Major Shareholders & Holdings控股股東蒲忠傑透過北京厚德義民、寧波厚德義民及樂普醫療持有權益,緊隨全球發售完成後(假設超額配股權未獲行使)將持有本公司股本總額約39.7%。
About this page

This page shows Lepu Bio (02157) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect